HIV Integrase Inhibitors and Entry Inhibitors

Daniel Bradshaw, Ranjababu Kulasegaram

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Integrase strand transfer inhibitors (INSTI) are therapeutic agents active against both HIV-1 and HIV-2. These drugs are now a preferred drug class for HIV treatment, owing to their virological efficacy, safety and tolerability. Four INSTI are currently approved for use, raltegravir, elvitegravir, dolutegravir and bictegravir. HIV-1 entry inhibitors are less often used but approved agents are maraviroc, a CCR5 receptor antagonist, and enfuvirtide, a fusion inhibitor.

Original languageEnglish
Title of host publicationEncyclopedia of Virology
Subtitle of host publicationVolume 1-5, Fourth Edition
Number of pages10
ISBN (Electronic)9780128145166
Publication statusPublished - 1 Jan 2020

Bibliographical note

Publisher Copyright:
© 2021 Elsevier Ltd. All rights reserved


  • 3TC
  • Abacavir
  • ABC
  • BCRP
  • BIC
  • Bictegravir
  • Breast cancer resistance protein
  • CAB
  • Cabotegravir
  • Dolutegravir
  • DTG
  • E/c/TAF/FTC
  • E/c/TDF/FTC
  • Elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine
  • Elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine
  • Emtricitabine
  • First heptad repeat
  • FTC
  • GFR
  • Glomerular filtration rate
  • HR1
  • Integrase strand transfer inhibitor
  • Lamivudine
  • Maraviroc
  • MATE
  • Multidrug and toxin extrusion transporter
  • MVC
  • OCT
  • Organic cation transporter
  • P-glycoprotein
  • P-gp
  • Pre exposure prophylaxis
  • PrEP
  • RAM
  • Resistance associated mutation
  • Rilpivirine
  • RPV
  • TAF
  • TDF
  • Tenofovir alafenamide
  • Tenofovir disoproxil fumarate
  • UGT
  • Uridine diphosphate glucuronosyltransferase


Dive into the research topics of 'HIV Integrase Inhibitors and Entry Inhibitors'. Together they form a unique fingerprint.

Cite this